BIOCORP
12.6.2019 18:09:07 CEST | Business Wire | Press release
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / PEA‐PME eligible), French company specializing in the development and manufacturing of medical devices and smart drug delivery systems, today announces that Mallya has obtained the CE 0459 mark as medical device class IIb.
Mallya is a smart sensor that turns conventional insulin pens into connected devices. Mallya records the key treatment information (selected dose, date and time of injection) and sends it to a dedicated mobile application. The app also allows the patient user to view a summary report of doses injected over a period of time (up to 90 days). This device allows an automatic recording of the doses injected with the highest accuracy, removing the need of manual logbooks. Mallya fits perfectly with new usages of patients using Continuous Glucose Monitoring Systems or Connected Blood glucose systems.
Today, Mallya is the only device available in its category to be labeled CE medical device, class IIb. The main benefits it offers to patients and health professionals are:
- A patented concept, a device tested in several studies,
- Ease of
installation and use does not disturb the usual use of the pen,
-
Reliability of information collected and transmitted to the mobile app.
Mallya will be rolled out this fall, supported by BIOCORP commercial partners.
ABOUT BIOCORP
Founded in 2004 in Issoire (near Clermont-Ferrand),
France, BIOCORP is a French company specializing in the development and
manufacturing of medical devices and innovative drug delivery systems.
It is listed as ‘Innovative Company’ by the French public investment
bank Bpifrance. With over twenty years of experience and more than 30
manufactured products, BIOCORP is a key player in the industry,
providing drug delivery solutions that meet the evolving needs of
patients. Today, BIOCORP continues to innovate in medical plastics, its
core business, and to market traditional devices (alternative to
aluminum capsules, syringe and vial administration systems) that have
been an important source of recurring income. Its solid expertise and
capacity to innovate have allowed the company to develop new
Internet-connected products, including MallyaTM
, a smart cap
for pen injectors that captures injection data and automatically
transmits data to a mobile app, helping patients to manage their
treatment. The company has a team of 45 employees. BIOCORP is listed on
Euronext since July 2015 (FR0012788065 – ALCOR).
For more
information, please visit www.biocorpsys.com
Follow
us on Twitter @BIOCORPSystems
View source version on businesswire.com: https://www.businesswire.com/news/home/20190612005727/en/
Contact:
BIOCORP Jacques Gardette CEO investisseurs@biocorp.fr
Éric Dessertenne Chief Operating Officer
Sylvaine DessardMarketing & Communication Director rp@biocorp.fr + 33 (0)6 88 69 72 85
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom